THERAPY DOSSIER · th-432406e71d2d

Bisperoxovanadium bpV(pic) delivered from poly-L-lactic acid microspheres, alone or combined with an acellular spinal cord scaffold

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30774313 ↗2019Reported benefit

Bisperoxovanadium protects against spinal cord injury by regulating autophagy via activation of ERK1/2 signaling.

RatSpinal cord injuryHemisection / partialSprague-DawleyMalen = n = 6 per injury group (SCI only, scaffold, PLLA/bpV(pic),…Local implantation of PLLA/bpV(pic) microspheres into the spinal cord lesion, with or without an acellular spinal cord scaffold20 ng/mL in vitro on rat neural stem cells; in vivo dose no…Implanted at the time of hemisection surgery

Model: Acute spinal cord injury, right-sided hemisections at T9 and T10 with a 2 mm gap created after laminectomy

bpV(pic) significantly improved BBB locomotor scores and preserved anterior horn motor neurons after hemisection, with the acellular scaffold plus bpV(pic) combination giving the largest effect. Treatment raised LC3B and Beclin1 and lowered p62, indicating increased autophagy, and reduced Bax/Bcl-2…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…